Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2018 12:50 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Receives Complete Response Letter from FDA for Buprenorphine NDA

PHOENIX, July 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...
July 25, 2018 08:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics to Report Second Quarter 2018 Results on Aug. 8

PHOENIX, July 25, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
June 18, 2018 12:58 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Provides an Update on Its Ongoing Transformation

PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
June 14, 2018 08:00 ET | Source: Insys Therapeutics, Inc.

Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection

PHOENIX, June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option...
June 04, 2018 16:15 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics to Present at Jefferies Global Healthcare Conference

PHOENIX, June 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
May 22, 2018 15:08 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray

PHOENIX, May 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
May 15, 2018 12:23 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts

PHOENIX, May 15, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
May 08, 2018 16:02 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
May 08, 2018 16:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Reports First Quarter 2018 Results

Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS® revenue continue PHOENIX, May 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc....
April 27, 2018 08:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome

PHOENIX, April 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...